KR20220024466A - 프레보텔라 제제 및 만성 폐쇄성 폐 질환(copd) 및 기타 폐 병태의 치료 - Google Patents

프레보텔라 제제 및 만성 폐쇄성 폐 질환(copd) 및 기타 폐 병태의 치료 Download PDF

Info

Publication number
KR20220024466A
KR20220024466A KR1020227000806A KR20227000806A KR20220024466A KR 20220024466 A KR20220024466 A KR 20220024466A KR 1020227000806 A KR1020227000806 A KR 1020227000806A KR 20227000806 A KR20227000806 A KR 20227000806A KR 20220024466 A KR20220024466 A KR 20220024466A
Authority
KR
South Korea
Prior art keywords
prevotella
histicola
infection
melaninogenica
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227000806A
Other languages
English (en)
Korean (ko)
Inventor
베나 타네자
Original Assignee
메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 filed Critical 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치
Publication of KR20220024466A publication Critical patent/KR20220024466A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227000806A 2019-06-17 2020-06-17 프레보텔라 제제 및 만성 폐쇄성 폐 질환(copd) 및 기타 폐 병태의 치료 Pending KR20220024466A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962862186P 2019-06-17 2019-06-17
US62/862,186 2019-06-17
PCT/US2020/038084 WO2020257248A1 (en) 2019-06-17 2020-06-17 Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions

Publications (1)

Publication Number Publication Date
KR20220024466A true KR20220024466A (ko) 2022-03-03

Family

ID=74037580

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227000806A Pending KR20220024466A (ko) 2019-06-17 2020-06-17 프레보텔라 제제 및 만성 폐쇄성 폐 질환(copd) 및 기타 폐 병태의 치료

Country Status (11)

Country Link
US (1) US20220296657A1 (cg-RX-API-DMAC10.html)
EP (1) EP3983067A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022537178A (cg-RX-API-DMAC10.html)
KR (1) KR20220024466A (cg-RX-API-DMAC10.html)
CN (1) CN114340732A (cg-RX-API-DMAC10.html)
AU (1) AU2020295393A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021025416A2 (cg-RX-API-DMAC10.html)
CA (1) CA3143597A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022000029A2 (cg-RX-API-DMAC10.html)
MX (1) MX2021015711A (cg-RX-API-DMAC10.html)
WO (1) WO2020257248A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses
EP4297762A1 (en) * 2021-02-26 2024-01-03 Evelo Biosciences, Inc. Compositions and methods for reducing cytokine expression
WO2022187064A1 (en) * 2021-03-01 2022-09-09 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
WO2023146843A1 (en) * 2022-01-25 2023-08-03 Evelo Biosciences, Inc. Extracellular vesicle compositions and methods of use
WO2023200837A1 (en) * 2022-04-13 2023-10-19 Evelo Biosciences, Inc. Compositions and methods of treating inflammation using prevotella histicola
US20250325598A1 (en) * 2022-05-06 2025-10-23 The Regents Of The University Of Colorado, A Body Corporate Immunobiotics for preventing bacterial pneumonia and methods of using the same
WO2024097250A1 (en) * 2022-10-31 2024-05-10 The Trustees Of Columbia University In The City Of New York Polymeric carrier for probiotics

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US20040131614A1 (en) * 2002-07-19 2004-07-08 Abbott Biotechnology Ltd. Treatment of pulmonary disorders using TNFalpha inhibitor
US20090257993A1 (en) * 2003-12-17 2009-10-15 M Rabet Laura Lactic Acid Producing Bacteria and Lung Function
RU2009133376A (ru) 2007-03-27 2011-05-10 Дзе Проктер Энд Гэмбл Компани (US) Способы и наборы для введения пробиотиков
WO2011053653A2 (en) * 2009-10-30 2011-05-05 Mayo Foundation For Medical Education And Research Prevotella histicola preparations and the treatment of autoimmune conditions
JP2014196260A (ja) * 2013-03-29 2014-10-16 公立大学法人奈良県立医科大学 慢性閉塞性肺疾患の予防又は治療用組成物
US10465224B2 (en) * 2015-02-03 2019-11-05 Mayo Foundation For Medical Education And Research Methods and materials for assessing and treating arthritis
KR20250161669A (ko) * 2015-09-09 2025-11-17 레비비코르 인코포레이션 이종 장기이식을 위한 멀티-형질전환 피그
ES2834950T3 (es) * 2017-02-28 2021-06-21 Prec Group Limited Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmunitaria a la infección por virus respiratorio
WO2019004668A1 (ko) * 2017-06-30 2019-01-03 주식회사 엠디헬스케어 프로테우스 속 세균 유래 나노소포 및 이의 용도
BR112020004347A2 (pt) * 2017-09-08 2020-09-08 Evelo Biosciences, Inc. vesículas extracelulares de prevotella
US20220031765A1 (en) * 2018-11-30 2022-02-03 Ospedale San Raffaele S.R.L. Bacterial strains for medical uses

Also Published As

Publication number Publication date
EP3983067A4 (en) 2023-06-14
JP2022537178A (ja) 2022-08-24
AU2020295393A1 (en) 2022-01-06
CN114340732A (zh) 2022-04-12
EP3983067A1 (en) 2022-04-20
CA3143597A1 (en) 2020-12-24
US20220296657A1 (en) 2022-09-22
BR112021025416A2 (pt) 2022-02-22
MX2021015711A (es) 2022-02-03
WO2020257248A1 (en) 2020-12-24
CO2022000029A2 (es) 2022-04-08

Similar Documents

Publication Publication Date Title
US20220296657A1 (en) Prevotella preparations and treating chronic obstructive pulmonary disease (copd) and other lung conditions
Sansores-España et al. Oral-gut-brain axis in experimental models of periodontitis: associating gut dysbiosis with neurodegenerative diseases
Lee et al. Anti-inflammatory and anti-allergic effects of kefir in a mouse asthma model
De Grove et al. Dysregulation of type 2 innate lymphoid cells and TH2 cells impairs pollutant-induced allergic airway responses
TWI797058B (zh) 包含細菌菌株之組合物
EP3204024B1 (en) Compositions comprising bacterial strains
Cheng et al. Oral osteomicrobiology: the role of oral microbiota in alveolar bone homeostasis
EP2590662B1 (fr) Complexe macromoleculaire provenant de bifidobacterium longum et utilisation dudit complexe pour prevenir et traiter les rhumatismes inflammatoires
TW202120109A (zh) 使用普雷沃菌屬治療ｔｈ２介導的病症之組成物及方法
US20020082296A1 (en) A method for treating an immune disorder with a purified mycobacterial mycolic acid
KR20050109928A (ko) 유산균으로부터 유래된 소염 활성
Tang et al. Porphyromonas endodontalis lipopolysaccharides induce RANKL by mouse osteoblast in a way different from that of Escherichia coli lipopolysaccharide
WO2001037865A1 (en) Compositions and methods for treatment of allergic disorders
Tian et al. Oral delivery of mouse β-defensin 14 (mBD14)-producing Lactococcus lactis NZ9000 attenuates experimental colitis in mice
Dong et al. Expression of retinoic acid receptors in intestinal mucosa and the effect of vitamin A on mucosal immunity
US11602551B2 (en) Use of inosine for the treatment of t-reg deficiency
Okajima et al. Free feeding of CpG-oligodeoxynucleotide particles prophylactically attenuates allergic airway inflammation and hyperresponsiveness in mice
US20220000976A1 (en) Methods and compositions for treating or preventing the development of food allergies
Kleuskens Local immune responses in eosinophilic esophagitis: Implications for disease pathophysiology and dietary management
Choi et al. Interplay of zinc deficiency, epithelial microdamage, and Escherichia coli infection in a mouse model of oral lichen planus
Baier Interleukin-33: new insights into the crosstalk between the mucosal immune system and the gut microbiota
IBRAEVA et al. SCIENCE & HEALTHCARE
Clancy et al. The handling of inhaled antigen within the respiratory tract
Turkoz RBPjk-Independent, NICD-Dependent Signals in Rbpj-/-Hair Follicle Keratinocytes Cause a Milder Phenotype in RBPjcKO Animals
Cruickshank et al. Intestinal Intraepithelial Lymphocyte-Enterocyte Crosstalk Regulates Production of Bactericidal Angiogenin 4 by Paneth Cells upon Microbial Challenge

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902